Amivantamab and lazertinib in treatment-naïve EGFR-mutated advanced non–small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS. This is an ASCO Meeting Abstract from the ...
The approval of immunotherapy combinations beginning in 2020 fundamentally altered that calculus, and the April 2025 ...
Adding nivolumab (Opdivo) instead of brentuximab vedotin (Adcetris) to the standard chemotherapy backbone of doxorubicin (Adriamycin), vinblastine, and dacarbazine (AVD) resulted in longer progression ...
Please provide your email address to receive an email when new articles are posted on . Patients who received nivolumab had longer DFS than those who received standard care. OS will be evaluated after ...
Pre-surgery treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab led to tumor control in 55% of patients with stage 3 cutaneous melanoma, according to the results of a ...
Intimal sarcomas (ISarc) of the cardiac chambers (CC) of the heart and great vessels (GV): A comprehensive genomic profiling (CGP) study. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...
Adjuvant therapy with nivolumab (Opdivo) was feasible and safe and appeared to prolong disease-free survival (DFS) in patients with completely resected Merkel cell carcinoma (MCC), interim results ...
A phase 2 trial evaluated the efficacy of nivolumab added to brachytherapy, external beam radiation therapy, and ADT in men with high-risk grade group 5 prostate cancer.
Please provide your email address to receive an email when new articles are posted on . Use of nivolumab in the neoadjuvant and adjuvant settings significantly extended EFS. A higher percentage of ...
The immune checkpoint inhibitor nivolumab (Opdivo) appears to prevent the transformation of oral proliferative leukoplakia (PL), a high-risk precancerous disease, into oral cancer, suggest the results ...
Nivolumab has recently been approved both in combination with fluoropyrimidine- and platinum-based combination chemotherapy and in combination with ipilimumab for the first-line treatment of adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results